Efficacy of hydroxyurea in providing transfusion independence in β-thalassemia. (åpner nytt vindu)

Ansari SH, Shamsi TS, Ashraf M, Perveen K, Farzana T, Bohray M, Erum S, Mehboob T.

Kilde‎: J Pediatr Hematol Oncol 2011;33(5):339-43.

Arkiv‎: PubMed 21602718

DOI‎: 10.1097/MPH.0b013e31821b0770

https://www.ncbi.nlm.nih.gov/pubmed/21602718 (åpner nytt vindu)

Gγ-Xmn I polymorphism: a significant determinant of β-thalassemia treatment without blood transfusion. (åpner nytt vindu)

Ansari SH, Shamsi TS, Munzir S, Khan MT, Erum S, Perveen K, Farzana T, Ashraf M, Mehboob T, Moinuddin M.

Kilde‎: J Pediatr Hematol Oncol 2013;35(4):e153-6.

Arkiv‎: PubMed 23389500

DOI‎: 10.1097/MPH.0b013e31827e8662

https://www.ncbi.nlm.nih.gov/pubmed/23389500 (åpner nytt vindu)

Efficacy of hydroxyurea (HU) in reduction of pack red cell (PRC) transfusion requirement among children having beta-thalassemia major: Karachi HU trial (KHUT). (åpner nytt vindu)

Ansari SH, Shamsi TS, Siddiqui FJ, Irfan M, Perveen K, Farzana T, Panjwani VK, Yousuf A, Mehboob T.

Kilde‎: J Pediatr Hematol Oncol 2007;29(11):743-6.

Arkiv‎: PubMed 17984691

DOI‎: 10.1097/MPH.0b013e318157fd75

https://www.ncbi.nlm.nih.gov/pubmed/17984691 (åpner nytt vindu)

Hydroxyurea can eliminate transfusion requirements in children with severe beta-thalassemia. (åpner nytt vindu)

Bradai M, Abad MT, Pissard S, Lamraoui F, Skopinski L, de Montalembert M.

Kilde‎: Blood 2003;102(4):1529-30.

Arkiv‎: PubMed 12702505

DOI‎: 10.1182/blood-2003-01-0117

https://www.ncbi.nlm.nih.gov/pubmed/12702505 (åpner nytt vindu)

Decreased transfusion needs associated with hydroxyurea therapy in Algerian patients with thalassemia major or intermedia. (åpner nytt vindu)

Bradai M, Pissard S, Abad MT, Dechartres A, Ribeil JA, Landais P, de Montalembert M.

Kilde‎: Transfusion 2007;47(10):1830-6.

Arkiv‎: PubMed 17880608

DOI‎: 10.1111/j.1537-2995.2007.01399.x

https://www.ncbi.nlm.nih.gov/pubmed/17880608 (åpner nytt vindu)

Hydroxyurea can reduce or eliminate transfusion requirements in children with major and intermediate thalassemia. (åpner nytt vindu)

Hashemi A, Abrishamkar M, Jenabzade AR, Eslami Z.

Kilde‎: Iran J Blood Cancer 2009;1(4):147-50.

Arkiv‎: IMEMR 107228

https://www.ijbc.ir/browse.php?a_id=4&sid=1&slc_lang=en (åpner nytt vindu)

Genotype-phenotype relationship of patients with β-thalassemia taking hydroxyurea: a 13-year experience in Iran. (åpner nytt vindu)

Karimi M, Haghpanah S, Farhadi A, Yavarian M.

Kilde‎: Int J Hematol 2012;95(1):51-6.

Arkiv‎: PubMed 22180324

DOI‎: 10.1007/s12185-011-0985-6

https://www.ncbi.nlm.nih.gov/pubmed/22180324 (åpner nytt vindu)

Fetal globin stimulant therapies in the beta-hemoglobinopathies: principles and current potential. (åpner nytt vindu)

Perrine SP.

Kilde‎: Pediatr Ann 2008;37(5):339-46.

Arkiv‎: PubMed 18543545

https://www.ncbi.nlm.nih.gov/pubmed/18543545 (åpner nytt vindu)

A randomised double-blind placebo-controlled clinical trial of oral hydroxyurea for transfusion-dependent β-thalassaemia. (åpner nytt vindu)

Yasara N, Wickramarathne N, Mettananda C, Silva I, Hameed N, Attanayaka K, Rodrigo R, Wickramasinghe N, Perera L, Manamperi A, Premawardhena A, Mettananda S

Kilde‎: Sci Rep. 2022;12(1):2752.

Arkiv‎: PubMed 35177777

DOI‎: 10.1038/s41598-022-06774-8

https://pubmed.ncbi.nlm.nih.gov/35177777/ (åpner nytt vindu)

Response to hydroxyurea treatment in Iranian transfusion-dependent beta-thalassemia patients. (åpner nytt vindu)

Yavarian M, Karimi M, Bakker E, Harteveld CL, Giordano PC.

Kilde‎: Haematologica 2004;89(10):1172-8.

Arkiv‎: PubMed 15477200

https://www.ncbi.nlm.nih.gov/pubmed/15477200 (åpner nytt vindu)

Hydroxyurea therapy in 49 patients with major beta-thalassemia. (åpner nytt vindu)

Zamani F, Shakeri R, Eslami SM, Razavi SM, Basi A.

Kilde‎: Arch Iran Med 2009;12(3):295-7.

Arkiv‎: PubMed 19400608

https://www.ncbi.nlm.nih.gov/pubmed/19400608 (åpner nytt vindu)

Use of hydroxyurea and recombinant erythropoietin in management of homozygous ß⁰ thalassemia. (åpner nytt vindu)

Kohli-Kumar M, Marandi H, Keller MA, Guertin K, Hvizdala E.

Kilde‎: J Pediatr Hematol Oncol 2002;24(9):777-8.

Arkiv‎: PubMed 12468925

https://www.ncbi.nlm.nih.gov/pubmed/12468925 (åpner nytt vindu)

Termination of transfusion dependence in beta-thalassemia: two-year experience with recombinant human erythropoietin. (åpner nytt vindu)

Nişli G, Kavakli K, Aydinok Y, Oztop S, Cetingül N.

Kilde‎: Pediatr Hematol Oncol 1997;14(3):285-7.

Arkiv‎: PubMed 9185215

https://www.ncbi.nlm.nih.gov/pubmed/9185215 (åpner nytt vindu)

Fetal globin gene inducers: novel agents and new potential. (åpner nytt vindu)

Perrine SP, Castaneda SA, Chui DH, Faller DV, Berenson RJ, Siritanaratku N, Fucharoen S.

Kilde‎: Ann N Y Acad Sci 2010;1202:158-64.

Arkiv‎: PubMed 20712788

DOI‎: 10.1111/j.1749-6632.2010.05593.x

https://www.ncbi.nlm.nih.gov/pubmed/20712788 (åpner nytt vindu)